Pharma Stocks Outlook for the week – 01 to 05.02.2016
Seen
continuing uptrend; Lupin earnings eyed
( www.rupeedesk.in )
Earnings
of Lupin, Pfizer and Cadila Healthcare will be the key triggers for their
stocks
next week, with the underlying bias for most pharmaceutical stocks expected to
be
positive after declining for three consecutive weeks. While Cadila Healthcare
and
Lupin
report their Oct-Dec earnings next Friday, Pfizer will be reporting its results
on
Wednesday.
Consolidated net sales of Lupin are expected to grow 6% on year on
account
of price hike in Fortamet generic and better traction in generics of Niaspan
and
Celebrex.
The
company's consolidated net profit, though, is seen falling 19% to 4.9 bln
rupees
due
to weak operational performance, as per the estimates. Cadila Healthcare is
seen
reporting
a 5% decline in its consolidated net profit at 3.7 bln rupees. Yesterday, the
stock
ended up 1.7% at 304.20 rupees. This week saw a near 11% rise in the shares of
Sun
Pharmaceutical Industries, India's largest pharmaceutical company with a market
share
of 8.8% as of December. Yesterday, a report in The Economic Times said that
Sun
Pharmaceutical has put on block some Ranbaxy brands which are low priority in
its
domestic market strategy or ones which may overlap with its own products.
Yesterday, the stock ended up 4.6% at 872.95 rupees on the report.